Business Description
Arcus Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US03969F1093
Total Employee Number:
601Description
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.27 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -0.32 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 2.07 | |||||
Beneish M-Score | -1.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.9 | |||||
3-Year EBITDA Growth Rate | 4.5 | |||||
3-Year EPS without NRI Growth Rate | 3.9 | |||||
3-Year Book Growth Rate | -17.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.7 | |||||
9-Day RSI | 45.02 | |||||
14-Day RSI | 51.16 | |||||
3-1 Month Momentum % | 2.03 | |||||
6-1 Month Momentum % | 10.97 | |||||
12-1 Month Momentum % | 167.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.04 | |||||
Quick Ratio | 4.04 | |||||
Cash Ratio | 3.93 | |||||
Days Sales Outstanding | 17.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.8 | |||||
Shareholder Yield % | -9.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -168.64 | |||||
Net Margin % | -156.36 | |||||
EBITDA Margin % | -148.31 | |||||
FCF Margin % | -206.78 | |||||
OCF Margin % | -206.78 | |||||
ROE % | -69.08 | |||||
ROA % | -34.54 | |||||
ROIC % | -187.74 | |||||
3-Year ROIIC % | 57.92 | |||||
ROC (Joel Greenblatt) % | -854.76 | |||||
ROCE % | -42.1 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 13 | |||||
PB Ratio | 6.7 | |||||
Price-to-Tangible-Book | 6.7 | |||||
EV-to-EBIT | -7.84 | |||||
EV-to-Forward-EBIT | -5.26 | |||||
EV-to-EBITDA | -8.04 | |||||
EV-to-Revenue | 11.93 | |||||
EV-to-Forward-Revenue | 46.03 | |||||
EV-to-FCF | -5.77 | |||||
Price-to-GF-Value | 2.17 | |||||
| Price-to-Net-Current-Asset-Value | 9.47 | |||||
| Price-to-Net-Cash | 10.08 | |||||
Earnings Yield (Greenblatt) % | -12.76 | |||||
FCF Yield % | -13.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:RCUS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arcus Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 236 | ||
| EPS (TTM) ($) | -3.18 | ||
| Beta | 1.3124 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 60.22 | ||
| 14-Day RSI | 51.16 | ||
| 14-Day ATR ($) | 1.447141 | ||
| 20-Day SMA ($) | 28.6195 | ||
| 12-1 Month Momentum % | 167.77 | ||
| 52-Week Range ($) | 8.84 - 31.735 | ||
| Shares Outstanding (Mil) | 125.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcus Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcus Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-28 | In 104 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 21 days | ||
| General meeting for 2026 | 2026-06-11 08:30 | 22.12 (-5.23%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:40 | 23.32 (-1.19%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 26.05 (+1.96%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 26.05 (+1.96%) | ||
| Guidance call for 2026 | 2026-03-09 11:20 | 22.11 (+1.47%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 16:30 | 20.19 (+5.76%) | ||
| Annual report for 2025 | 2026-02-25 | 20.19 (+5.76%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 20.19 (+5.76%) |
Show
Entries
Arcus Biosciences Inc Frequently Asked Questions
What is Arcus Biosciences Inc(RCUS)'s stock price today?
The current price of RCUS is $28.02. The 52 week high of RCUS is $31.74 and 52 week low is $8.84.
When is next earnings date of Arcus Biosciences Inc(RCUS)?
The next earnings date of Arcus Biosciences Inc(RCUS) is 2026-08-06 Est..
Does Arcus Biosciences Inc(RCUS) pay dividends? If so, how much?
Arcus Biosciences Inc(RCUS) does not pay dividend.
Guru Commentaries on NYSE:RCUS
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers